On the basis of these evidences, in a breast cancer setting it is becoming important to discriminate ERα-positive and ERα-negative tumors to specifically assess the best therapeutic approaches designed to impact adiponectin functions [64]. Here, ADIPOQ is linked to breast carcinoma.